Literature DB >> 15710217

Amelioration of microcirculatory damage by an endothelin A receptor antagonist in a rat model of reversible acute liver failure.

Daniel Palmes1, Sebastian Skawran, Udo Stratmann, Barbara Armann, Evgeny Minin, Hermann Herbst, Hans-Ullrich Spiegel.   

Abstract

BACKGROUND/AIMS: Hepatocellular damage in acute liver failure (ALF) is aggravated by proinflammatory and cytotoxic mediators released from sinusoidal-lining cells. We studied a selective endothelin A receptor (ETAR) antagonist for its potential influence on the microcirculation in the setting of ALF.
METHODS: Seventy Wistar rats were divided into five groups: (I) induction of ALF by a 70% liver resection combined with injection of 400 microg/kg endotoxin, (II) ALF treated with the ETAR antagonist LU 135252 (1 mg/kg b.w. i.v.), (III) sham operation, (IV) injection of endotoxin, (V) 70% liver resection. Liver microcirculation was measured by intravital microscopy. Parenchymal injury, growth fractions, endothelin (ET)-1 and ETAR were studied by histology and immunohistology. Survival, liver function, and morphology were followed up to 14 days.
RESULTS: 100% mortality, impaired liver function, widespread endothelial lesions, highest ET-1 and ETAR levels, a decreased perfusion rate, reduced sinusoidal diameter, as well as an increase in both leukocyte-endothelium interactions and sinusoidal blood flow were observed after induction of ALF. ETAR antagonist-treated rats showed decreased ET-1 and ETAR levels as well as improved microcirculatory function, morphology, liver function, and 85% survival.
CONCLUSIONS: Microcirculatory disturbances correlate with liver dysfunction in ALF. ETAR blockade represents a new therapeutic approach to ALF by reducing microcirculatory lesions and their sequelae.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15710217     DOI: 10.1016/j.jhep.2004.11.019

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  5 in total

1.  Hyperbaric oxygen therapy reduces the severity of ischaemia, preservation and reperfusion injury in a rat model of liver transplantation.

Authors:  Nhut Quang Tran; Caterina Malcontenti-Wilson; Soukena Hammoud; Ian Millar; Chris Christophi; Vijayaragavan Muralidharan
Journal:  HPB (Oxford)       Date:  2011-11-13       Impact factor: 3.647

2.  Endothelin-1 receptor A blocker darusentan decreases hepatic changes and improves liver repopulation after cell transplantation in rats.

Authors:  Ralf Bahde; Sorabh Kapoor; Preeti Viswanathan; Hans-Ullrich Spiegel; Sanjeev Gupta
Journal:  Hepatology       Date:  2014-01-16       Impact factor: 17.425

Review 3.  [Diagnosis and therapies for acute liver failure: scientific developments].

Authors:  M Ott; T Cantz; A Schneider; M P Manns
Journal:  Internist (Berl)       Date:  2014-11       Impact factor: 0.743

4.  Dual endothelin-converting enzyme/neutral endopeptidase blockade in rats with D-galactosamine-induced liver failure.

Authors:  Berthold Hocher; S Heiden; K von Websky; J Rahnenführe; P Kalk; T Pfab
Journal:  Eur J Med Res       Date:  2011-06-21       Impact factor: 2.175

5.  Microcirculatory disturbance in acute liver injury.

Authors:  Akifumi Kuwano; Miho Kurokawa; Motoyuki Kohjima; Koji Imoto; Shigeki Tashiro; Hideo Suzuki; Masatake Tanaka; Seiji Okada; Masaki Kato; Yoshihiro Ogawa
Journal:  Exp Ther Med       Date:  2021-04-09       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.